CAS 11041-12-6|Colestyramine
| Common Name | Colestyramine | ||
|---|---|---|---|
| CAS Number | 11041-12-6 | Molecular Weight | 331.923 |
| Density | / | Boiling Point | / |
| Molecular Formula | C21H30ClN | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | / |
Names
| Name | cholestyramine resin |
|---|---|
| Synonym | More Synonyms |
Colestyramine BiologicalActivity
| Description | Colestyramine (Cholestyramine) is a bile acid binding resin and can inhibit intestinal bile acid absorption which results in the increasing bile acid synthesis from cholesterol. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Cardiovascular Disease |
| In Vivo | Colestyramine (Cholestyramine) is a bile acid binding resin and can inhibit intestinal bile acid absorption which results in the increasing bile acid synthesis from cholesterol[1]. Results reveal that GSPE treatment alone, and co-administration with Colestyramine (CHY), regulate BA, cholesterol and TG metabolism differently compare to Colestyramine (CHY) administration alone. Notably, GSPE decreases intestinal apical sodium-dependent bile acid transporter (Asbt) gene expression, while Colestyramine (CHY) significantly induces expression. Administration with GSPE or Colestyramine (CHY) robustly induces hepatic BA biosynthetic gene expression, especially cholesterol 7α-hydroxylase (Cyp7a1), compare to control, while co-administration further enhances expression. Treatment with Colestyramine (CHY) induces both intestinal and hepatic cholesterologenic gene expression, while co-administration with GSPE attenuates the Colestyramine (CHY)-inducing increase in the liver but not in the intestine. Colestyramine (CHY) also induces hepatic lipogenic gene expression, which is attenuated by co-administration with GSPE[2]. |
| Animal Admin | Mice are purchased at 7 weeks of age and allowed to acclimate for one week. At 8-weeks of age the mice are given either a control or a 2% Colestyramine (cholestyramine)-supplementing diet for 4 weeks (n=18 per group). Body weight for each mouse is recorded weekly. After 4 weeks, the mice in each group are randomly assigned to one of two treatment groups and orally gavaged with either vehicle (water) or GSPE (250 mg/kg) and terminated 14 hours later (n=9 per experimental group). The four treatment groups are as follows: 1. CON: Control diet for 4 weeks following by oral gavage with vehicle (water) for 14 hrs; 2. GSPE: Control diet for 4 weeks following by oral gavage with 250 mg/kg GSPE for 14 hrs; 3.CHY Colestyramine (cholestyramine): 2% Colestyramine (cholestyramine)-supplementing diet for 4 weeks following by oral gavage with vehicle for 14 hrs; and 4. CHY Colestyramine (cholestyramine)+GSPE: 2% cholestyramine-supplementing diet for 4 weeks following by oral gavage with 250 mg/kg GSPE for 14 hrs. Blood is collected from the orbital plexus under isoflurane anesthesia, and intestines and livers are snap-frozen in liquid nitrogen and stored at -80°C until use. At the start of the 14 hr experiment mice are placed into clean cages, and feces are manually collected at the end of the study[2]. |
| References | [1]. Maugeais C, et al. rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment. Atherosclerosis. 2013 Jul;229(1):94-101. [2]. Rebecca M. Heidker, et al. Grape Seed Procyanidins and Cholestyramine Differentially Alter Bile Acid and Cholesterol Homeostatic Gene Expression in Mouse Intestine and Liver. PLoS One. 2016; 11(4): e0154305. |
Chemical & Physical Properties
| Molecular Formula | C21H30ClN |
|---|---|
| Molecular Weight | 331.923 |
| Exact Mass | 331.206665 |
| Water Solubility | Insoluble in water, in methylene chloride and in ethanol (96 per cent). |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| Safety Phrases | S22-24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | FZ9310000 |
Articles33
More Articles| A review of the diagnosis and treatment of Ochratoxin A inhalational exposure associated with human illness and kidney disease including focal segmental glomerulosclerosis. J. Environ. Public Health 2012 , 835059, (2012) Ochratoxin A (OTA) exposure via ingestion and inhalation has been described in the literature to cause kidney disease in both animals and humans. This paper reviews Ochratoxin A and its relationship t... | |
| Using resin to generate a non-invasive intestinal bile-depleted rat model was unsuccessful. Eur. J. Pharm. Sci. 47(2) , 347-51, (2012) The purpose of this study was to evaluate if a rat model, based upon co-administration of the anion-exchanging resin, cholestyramine, could replace surgery when evaluating the importance of bile on dr... | |
| [Antidiarrheal drugs for chronic diarrhea]. Dtsch. Med. Wochenschr. 138(45) , 2309-12, (2013) Chronic diarrhea can be caused by multiple disease entities. Basic diagnostic tests are required in order to administer specific therapies whenever possible. If no specific treatment can be used, a sy... |
Synonyms
| colestyramin |
| CHOLESTYRAMINE RESIN |
| 4-[3-(4-Ethylphenyl)butyl]-N,N,N-trimethylanilinium chloride |
| Benzenaminium, 4-[3-(4-ethylphenyl)butyl]-N,N,N-trimethyl-, chloride (1:1) |
| cholestyraminechloride |
| cuemid |
| polystyrenebenzyltrimethylaminoniumchloride |
| quantalan |
| MFCD00130784 |
| CHOLESTYRAMINE |
| EINECS 234-270-8 |
| DOWEX 1 X 2 CL-FORM |
| Colestyramine |
